Table 2.
Dyslipidemia treatment in the study groups.
| Dyslipidemia Initial Treatment, no. (%) | Total pts N = 3439 |
Group 1—194 pts Very High Risk |
Group—1611 pts High Risk |
Group 3—1634 pts Medium and Low Risk |
p-Value (Pearson Chi-Square) |
|---|---|---|---|---|---|
| Statins, no. (%)—total | 1619 (47.1%) | 181 (93.3%) | 821 (51.0%) | 617 (37.8%) | 0.000001 |
| Rosuvastatin | 668 (41.3%) | 72 (39.8%) | 374 (45.6%) | 222 (36.0%) | |
| Atorvastatin | 866 (53.5%) | 104 (57.5%) | 397 (48.4%) | 365 (59.2%) | |
| Simvastatin | 83 (5.1%) | 5 (2.8%) | 48 (5.8%) | 30 (4.9%) | |
| Other statins | 2 (0.2) | 0 (0.0%) | 2 (0.2%) | 0 (0.0%) | |
| Fenofibrat | 237 (6.9%) | 33 (17.0%) | 139 (8.6%) | 65 (4.0%) | 0.000001 |
| Ezetimib | 196 (5.7%) | 16 (8.2%) | 107 (6.6%) | 73 (4.5%) | 0.008151 |
| Omega 3 | 753 (21.9%) | 59 (30.4%) | 349 (21.7%) | 345 (21.1%) | 0.016274 |
| Combination (statins + ezetimib) | 206 (6.0%) | 37 (19.1%) | 126 (7.8%) | 43 (2.6%) | 0.000001 |